Aurinia Pharmaceuticals Inc [AUPH] stock prices are up 2.15% to $9.24 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The AUPH shares have gain 1.93% over the last week, with a monthly amount glided 23.60%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Oppenheimer downgraded its rating to Perform on November 04, 2022. Oppenheimer upgraded its rating to a Outperform and decreased its price target to $31 on December 10, 2021. Oppenheimer downgraded its rating to a Perform but $32 remained the price target by the analyst firm on October 28, 2021. H.C. Wainwright reiterated a Buy rating for this stock on January 25, 2021, and upped its price target to $35. In a note dated November 03, 2020, H.C. Wainwright reiterated an Buy rating on this stock and revised its target price from $34 to $28.
The stock price of Aurinia Pharmaceuticals Inc [AUPH] has been fluctuating between $5.20 and $10.67 over the past year. Currently, Wall Street analysts expect the stock to reach $10.75 within the next 12 months. Aurinia Pharmaceuticals Inc [NASDAQ: AUPH] shares were valued at $9.24 at the most recent close of the market. An investor can expect a potential return of 16.34% based on the average AUPH price forecast.
Analyzing the AUPH fundamentals
The Aurinia Pharmaceuticals Inc [NASDAQ:AUPH] reported sales of 260.11M for trailing twelve months, representing a surge of 22.41%. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at 0.2%, Pretax Profit Margin comes in at 0.24%, and Net Profit Margin reading is 0.23%. To continue investigating profitability, this company’s Return on Assets is posted at 0.12, Equity is 0.17 and Total Capital is 0.12. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.24.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.79 points at the first support level, and at 8.33 for the second support level. However, for the 1st resistance point, the stock is sitting at 9.77, and for the 2nd resistance point, it is at 10.29.
Ratios To Look Out For
It’s worth pointing out that Aurinia Pharmaceuticals Inc [NASDAQ:AUPH]’s Current Ratio is 5.23. As well, the Quick Ratio is 4.63, while the Cash Ratio is 0.68. Considering the valuation of this stock, the price to sales ratio is 4.80, the price to book ratio is 3.66 and price to earnings (TTM) ratio is 21.62.
Transactions by insiders
Recent insider trading involved Keenan Greg, Chief Medical Officer, that happened on Mar 07 ’25 when 8305.0 shares were sold. Chief Executive Officer, Greenleaf Peter completed a deal on Mar 03 ’25 to sell 0.2 million shares. Meanwhile, Chief Executive Officer Greenleaf Peter sold 0.16 million shares on Mar 04 ’25.
